Novel cytotoxic agents in the treatment of metastatic breast cancer

Sean Warsch, Alberto J. Montero, Stefan Glück

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Breast cancer is the most common cancer affecting women worldwide, comprising approximately 20% of all cancers. Although many advances in the treatment of this disease have been made and mortality of early breast cancer improved over the past three decades, metastatic breast cancer (MBC) remains an incurable disease. Cytotoxic chemotherapy continues to play a major role in the treatment of MBC and has been recently combined with biologic agents such as monoclonal antibodies or kinase inhibitors. Over the past decade, several novel cytotoxic chemotherapies have been evaluated in clinical trials. Encouraging results have been observed with novel anti-microtubule agents, with recent US Food and Drug Administration approval of eribulin in 2010. Other novel cytotoxic agents currently under clinical development include novel anti-microtubule drugs, platinum compounds, and anti-angiogenic agents combined with chemotherapy. Here, we review all the major novel cytotoxic agents that have undergone clinical study over the past 5 years for the treatment of MBC.

Original languageEnglish (US)
Pages (from-to)75-82
Number of pages8
JournalCurrent Breast Cancer Reports
Issue number1
StatePublished - Mar 2012


  • Anti-angiogenesis
  • Anti-microtubule agents
  • Bevacizumab
  • Breast Cancer
  • Chemotherapy
  • Cytotoxic chemotherapy
  • Eribulin
  • Metastases
  • Metastatic
  • Platinum compounds
  • Taxanes
  • Topoisomerase inhibitors
  • Trabectedin

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Novel cytotoxic agents in the treatment of metastatic breast cancer'. Together they form a unique fingerprint.

Cite this